Novartis AG’s top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the Swiss drugmaker has said it could be worth.
Search
Recent Posts
- Shopify, BlackBerry develop COVID-19 app; Canada to roll out voluntary tests
- Ahead of Trump rally in Oklahoma, coronavirus cases surge in several states
- Amazon to use AI tech in its warehouses to enforce social distancing
- China's new virus outbreak needs further testing after 'hypothesis' on cause: WHO
- Record spikes in new coronavirus cases, hospitalizations sweep parts of U.S.
- U.S. CDC reports 2,038,344 coronavirus cases
- Coronavirus hitting the Americas hardest says World Health Organization
- Only French victims of faulty breast implant may claim damages, EU court says
- WHO hopes to work with U.S. on Ebola despite Trump criticism over COVID-19
- Germany to extend virus-related travel ban for non-European countries
- France's new confirmed cases of coronavirus slow down
- U.S. coronavirus deaths top 110,000 as cases approach 2 million: Reuters tally
- Indonesia reports biggest daily rise in coronavirus infections
- Factbox: What the WHO recommends on face masks
- Vaccines group raises $8.8 billion for immunisation plans for poor countries
- Sanofi to run consultations over restart of hydroxychloroquine trials
- 'A great sadness': Bolivia strains under COVID-19 as cases top 10,000
- UK COVID-19 confirmed death toll rises to 39,045
- Thailand's parliament approves $58 billion economic package to ease virus impact
- Drugs standards group nixes plan to kick pharma's crab blood habit